Drugs / Meningococcal group A, C, W-135, and Y conjugate vaccine
Meningococcal group A, C, W-135, and Y conjugate vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04490018 Comparator | Mar 2021 → May 2022 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal group A, C, W-135, and Y conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04490018 ↗ |
| Modality | Vaccine | “another quadrivalent meningococcal conjugate vaccine (MCV4-TT; Nimenrix®)” PMID 38955966 ↗ Jul 2024 |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT04490018 ↗ |